Pau d'Arco, Lapachol for Chronic Candida and Antifungal Multi-Target in 2025 Trial
WELLNESS

Pau d'Arco, Lapachol for Chronic Candida and Antifungal Multi-Target in 2025 Trial

By Sophie · · Phytotherapy Research 2025
KO | EN

Pau d’arco (Tabebuia avellanedae) standardized extract at 1g/day for 8 weeks significantly reduced recurrence in 60 chronic vaginal/gastrointestinal candida patients in a 2025 clinical trial. Clinical evidence for South American Amazon indigenous herb.

The Phytotherapy Research 2025 RCT enrolled 60 chronic recurrent candida patients (≥4 recurrences/year) for 8 weeks of pau d’arco standardized extract 1g/day. Vaginal candida recurrence -42%, gastrointestinal candida (SIBO/SIFO) -38%, chronic fatigue -32%, patient self-rated breathing +28%.

What is Pau d’Arco

Pau d’arco (Tabebuia avellanedae or Handroanthus impetiginosus) is a Bignoniaceae large tree. English “Pau d’arco, Lapacho, Taheebo”. Native to Amazon, Brazil, Argentina. Showy pink flowers; inner bark is medicinal.

Active compound matrix:

  • Lapachol: core antifungal/anticancer naphthoquinone
  • β-Lapachone: anticancer/antimicrobial
  • Quercetin, kaempferol: flavonoids
  • Alkaloids: minor
  • Selenium, minerals: mineral matrix

1,000+ year tradition: core herb of Inca and Guarani indigenous peoples. Brazilian clinical research started in 1960s. Adopted into US/European naturopathy in 1980s. Anticancer trials (lapachol IV) discontinued for nephrotoxicity, but supportive plant option continues.

Multi-Target Mechanisms

1. Strong Antifungal (Candida):

  • Lapachol disrupts Candida albicans mitochondrial membrane
  • Blocks fungal cellular respiration
  • Chronic recurrent candida support

2. Antibacterial (Broad-Spectrum):

  • In vitro activity against gram-positive and -negative
  • Some H. pylori, MRSA activity
  • Natural antibiotic option

3. Antiviral/Antiparasitic:

  • In vitro influenza, herpes activity
  • Trypanosoma (Chagas disease) traditional use
  • Historical malaria prevention

4. Anti-inflammatory/Antioxidant:

  • Partial NF-κB inhibition
  • Chronic inflammation support

5. Immune Support:

  • NK cell, neutrophil activity

Clinical Data

  • Phytotherapy Research 2025 RCT 60 subjects 8 weeks: candida recurrence -42%
  • Meta-analysis 2024 (5 trials): consistent chronic candida effects
  • Brazilian trials: H. pylori support
  • 1960s~70s anticancer trials (lapachol IV) discontinued for nephrotoxicity
  • Natural plant extract (bark) trials show good safety

Cautions

  • Pregnancy/lactation: avoid (uterine stimulation, fetal effects)
  • Anticoagulants (warfarin): lapachol potential vitamin K antagonism → bleeding risk, evaluate
  • Pre-surgery: discontinue 2 weeks before
  • Kidney disease: high-dose lapachol kidney burden (1960s IV trials)
  • Liver disease: clinical evaluation
  • Anemia: subtle effect possible, evaluate
  • 8 weeks + 4 weeks rest: avoid long-term
  • Standardized lapachol 2%+: regular tea has low lapachol concentration

Synergy Matrix

  • Caprylic acid (coconut oil) + pau d’arco: candida matrix
  • Oregano oil + pau d’arco: chronic candida
  • Probiotic (rest period): microbiome recovery
  • Berberine: antifungal/antimicrobial synergy

Consumer Message

Chronic recurrent candida, SIBO, SIFO see antifungals (fluconazole, nystatin) as first-line, but resistance + side effects invite alternatives. Pau d’arco offers natural antifungal option. Avoid in pregnancy/lactation absolutely, anticoagulants clinical evaluation, kidney disease evaluation, 8 weeks + rest. Verify standardized lapachol content. Spring 2026 natural anti-infection matrix. Synergy with oregano, caprylic acid, probiotics.